Trials / Completed
CompletedNCT01025544
Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China
A Phase III Open Label, Multi-Center Pediatric Study in China Comparing Booster Doses of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b (Hib) Infection
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 846 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 12 Months – 18 Months
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety and immunogenicity of booster doses of the two vaccines used to prevent Haemophilus influenzae type b infections in children 12-18 months of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) | Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines. |
| BIOLOGICAL | Hiberix (Haemophilus influenzae type b (Hib) vaccine) | Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines. |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2009-12-01
- Completion
- 2010-04-01
- First posted
- 2009-12-03
- Last updated
- 2011-12-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01025544. Inclusion in this directory is not an endorsement.